[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.2967/jnumed.124.267627

[¹⁸F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [¹⁸F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status

Joanna K. Weeks & Lilie L. Lin et al. · 2025-01-03

Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (

Links

DOI PubMed

Journal

Journal of Nuclear Medicine

Authors

Joanna K. Weeks, Austin R. Pantel, Sarah B. Gitto, Fang Liu, Erin K. Schubert, Daniel A. Pryma, Michael D. Farwell, David A. Mankoff, Robert H. Mach, Fiona Simpkins, Lilie L. Lin